Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding
Others
Ratios

Viking Therapeutics (VKTX) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Viking Therapeutics (VKTX) over the last 12 years, with Q4 2025 value amounting to -$157.7 million.

  • Viking Therapeutics' Consolidated Net Income fell 34556.42% to -$157.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$359.6 million, marking a year-over-year decrease of 22700.01%. This contributed to the annual value of -$359.6 million for FY2025, which is 22700.01% down from last year.
  • Viking Therapeutics' Consolidated Net Income amounted to -$157.7 million in Q4 2025, which was down 34556.42% from -$90.8 million recorded in Q3 2025.
  • Viking Therapeutics' Consolidated Net Income's 5-year high stood at -$12.4 million during Q4 2021, with a 5-year trough of -$157.7 million in Q4 2025.
  • For the 5-year period, Viking Therapeutics' Consolidated Net Income averaged around -$34.0 million, with its median value being -$20.9 million (2022).
  • In the last 5 years, Viking Therapeutics' Consolidated Net Income plummeted by 1044.42% in 2023 and then tumbled by 34556.42% in 2025.
  • Viking Therapeutics' Consolidated Net Income (Quarter) stood at -$12.4 million in 2021, then crashed by 58.29% to -$19.6 million in 2022, then dropped by 25.72% to -$24.6 million in 2023, then crashed by 44.0% to -$35.4 million in 2024, then plummeted by 345.56% to -$157.7 million in 2025.
  • Its Consolidated Net Income was -$157.7 million in Q4 2025, compared to -$90.8 million in Q3 2025 and -$65.5 million in Q2 2025.